Armata Pharmaceuticals, Inc. - Laporan Laba Rugi (TTM)

Armata Pharmaceuticals, Inc.
US ˙ NYSEAM ˙ US04216R1023

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Armata Pharmaceuticals, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 0 1 2 3 4 4 5 5 5 6 5 4 4 5 5 4 5 5 5 7
Change (%) 157.99 129.53 60.19 31.82 12.16 3.80 15.40 1.62 1.14 -7.99 -17.82 -2.71 11.77 3.75 -20.86 47.00 -5.36 -9.18 46.16
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 10 14 16 19 20 20 24 27 30 35 37 36 11 34 32 16 34 34 32 35
Change (%) 49.96 11.08 16.06 8.38 -0.82 18.38 16.02 10.09 15.71 4.50 -2.08 -70.65 221.10 -4.70 -49.41 105.87 2.70 -7.51 8.48
% of Revenue 3,019.44 1,755.04 849.34 615.37 505.92 447.36 510.19 512.93 555.67 635.75 722.04 860.31 259.55 745.64 684.87 437.81 613.13 665.37 677.57 502.88
Gross Operating Profit -9 -14 -14 -16 -16 -16 -19 -22 -25 -30 -32 -32 -6 -29 -27 -13 -28 -29 -27 -28
Change (%) 46.26 3.92 10.17 3.83 -4.02 22.57 16.17 12.14 18.91 6.83 0.45 -79.58 352.30 -6.01 -54.29 123.30 4.27 -7.22 1.95
% of Revenue -2,919.44 -1,655.04 -749.34 -515.37 -405.92 -347.36 -410.19 -412.93 -455.67 -535.75 -622.04 -760.31 -159.55 -645.64 -584.87 -337.81 -513.13 -565.37 -577.57 -402.88
SG&A 10 8 8 8 8 8 8 8 8 7 8 8 10 12 12 13 13 13 13 12
Change (%) -16.45 -0.25 2.09 -0.95 3.06 -2.03 -0.69 -2.57 -5.26 7.46 3.34 24.47 13.32 5.49 8.86 -2.53 1.10 0.57 -6.18
% of Revenue 2,988.71 967.92 420.65 268.08 201.43 185.09 174.70 150.35 144.14 135.02 157.70 198.30 253.70 257.21 261.52 359.72 238.52 254.81 282.17 181.12
R&D 25 16 0 -5
Change (%) -97.62
% of Revenue 614.36 433.34 7.02 -69.60
OpEx 19 22 24 27 28 28 32 36 38 42 45 44 46 45 44 46 47 48 45 42
Change (%) 16.93 7.05 11.43 5.55 0.28 12.40 11.76 7.22 11.39 5.02 -1.11 3.63 -0.60 -2.09 2.93 2.55 1.42 -5.28 -6.43
% of Revenue 6,008.15 2,722.96 1,269.98 883.44 707.35 632.45 684.88 663.28 699.82 770.77 879.74 1,058.61 1,127.62 1,002.85 946.39 1,230.87 858.68 920.18 959.74 614.40
Operating Income -19 -22 -22 -24 -24 -24 -27 -30 -33 -37 -40 -40 -42 -41 -40 -42 -41 -42 -40 -35
Change (%) 14.54 2.38 7.27 2.19 -1.67 14.02 11.13 8.22 13.10 6.96 1.03 4.29 -1.80 -2.73 5.75 -1.38 2.31 -4.80 -12.55
% of Revenue -5,908.15 -2,622.96 -1,169.98 -783.44 -607.35 -532.45 -584.88 -563.28 -599.82 -670.77 -779.74 -958.61 -1,027.62 -902.85 -846.39 -1,130.87 -758.68 -820.18 -859.74 -514.40
Interest Expense -1 -1 -1 -0 -0 -0 -0 -0 0 -1 -3 -4 -7 -9 -11 -13 -14
Change (%) -4.27 -15.45 -26.74 -38.05 -73.44 -96.88 -0.00 -100.00 123.30 69.31 61.13 24.39 20.55 16.59 8.70
% of Revenue -205.64 -76.31 -28.11 -12.86 -6.04 -1.43 -0.04 -0.04 0.00 -29.02 -57.98 -94.62 -192.63 -163.00 -207.61 -266.52 -198.22
Net Income -20 -22 -23 -24 -24 -23 -26 -29 -33 -37 -43 -37 -60 -69 -80 -67 -41 -19 -0 -26
Change (%) 10.12 1.88 6.57 -1.45 -2.43 14.16 11.43 10.85 13.07 15.48 -13.29 61.00 16.02 15.25 -15.75 -38.30 -54.27 -97.75 5,934.51
% of Revenue -6,314.42 -2,695.14 -1,196.29 -795.84 -594.94 -517.55 -569.21 -549.64 -599.52 -670.24 -841.22 -887.52 -1,468.71 -1,524.51 -1,693.47 -1,802.72 -756.59 -365.60 -9.07 -374.30

Source: Capital IQ

Other Listings
DE:TG1N € 2.44
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista